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Abstract 
Background 
Onychomycosis is a chronic, fungal infection of the nails. Complete cure remains 
challenging, but oral antifungal medications have been successful in managing the fungus for 
a significant proportion of patients. Treatment with these drugs can be continuous or 
intermittent, albeit the evidence on their relative efficacies remains unclear. 
Objective 
To determine the relative effectiveness and safety of pulse versus continuous administration, 
of three common oral therapies for dermatophyte onychomycosis, by conducting multiple‐
treatment meta‐analysis. 
Methods 
This systematic review and network meta‐analysis compared the efficacy (as per mycological 
cure) and adverse event rates of three oral antifungal medications in the treatment of 
dermatophyte toenail onychomycosis, namely terbinafine, itraconazole and fluconazole. A 
total of 30 studies were included in the systematic review, while 22 were included in the 
network meta‐analysis. 
Results 
The likelihood of mycological cure was not significantly different between continuous and 
pulse regimens for each of terbinafine and itraconazole. Us  of continuous terbinafine for 
24 weeks – but not 12 weeks – was significantly more likely to result in mycological cure 
than continuous itraconazole for 12 weeks or weekly fluconazole for 9–12 months. Rank 
probabilities demonstrated that 24‐week continuous treatment of terbinafine was the most 
effective. There were no significant differences in the likelihood of adverse events between 
any continuous and pulse regimens of terbinafine, itraconazole and fluconazole. Drug 
treatments were similar to placebo in terms of their likelihood of producing adverse events.  
Conclusion 
More knowledge about the fungal life cycle and drugs’ pharmacokinetics in nail and plasma 
could further explain the relative efficacy and safety of the pulse and continuous treatment 
regimens. Our results indicate that in the treatment of dermatophyte toenail onychomycosis, 
the continuous and pulse regimens for terbinafine and itraconazole have similar efficacies and 
rates of adverse events. 
INTRODUCTION 
Onychomycosis is a persistent fungal infection of the nails and adjacent skin, manifesting as 
discoloration, thickening of the nail and onycholysis.1 It is the most common nail pathology 
accounting for 90% of toenail infections worldwide.1 Most cases of onychomycosis are 
caused by dermatophytes, namely Trichophyton (T. rubrum and T. mentagrophytes) and 
Epidermophyton.2 Onychomycosis is considered a chronic infection and can be difficult to 
treat, especially in susceptible populations such as those with diabetes, poor peripheral 
circulation, HIV and immunosuppression and the elderly.3-7 Additional factors that can 
contribute to disease progression or recurrence include humid environments, occlusive 
footwear, nail injuries or genetic predisposition.8, 9 
The goal of treatment is to completely eradicate the fungal organism and return the nail to a 
clear and healthy baseline. Mycological cure and complete cure are two treatment endpoints 
used to evaluate cure. Mycological cure is defined by negative potassium hydroxide (KOH) 
preparation and negative fungal culture, whereas complete cure is defined as 100% clear nail
in addition to mycological cure. The options for treating onychomycosis have become 
broader within the last two decades. Some of the most effective treatments for this condition 
are oral antifungal medications, namely terbinafine, itraconazole and fluconazole. Typically, 
these antifungal agents generate high mycological cure rates and are considered safe for most 
patients.10 They can be used continuously for several weeks or intermittently (pulsed) at a 
higher dose. Previous meta‐analyses of pulse and continuous therapies have generated 
ambiguous results – for example, continuous terbinafine resulted in a higher mycological 
cure than intermittent terbinafine, yet both result in similar complete cure, for which 
mycological cure is a prerequisite.11 In the case of itraconazole, the pulsed treatment resulted 
in better mycological and complete cure rates.12 There are few head‐to‐head clinical studies 
and no meta‐analyses comparing regimens of terbinafine to regimens of itraconazole.  
Network meta‐analysis (NMA) indirectly compares interventions using a common treatment 
group (e.g. placebo) to combine studies that make different comparisons into the same 
analysis.13 The NMA gathers information indirectly, allowing for estimation of comparative 
effects that have not been investigated head‐to‐head in randomized controlled trials (RCTs).14 
To visualize and interpret the evidence produced by oral antifungal pulse and continuous 
therapies, a network meta‐analysis (NMA) was conducted.15 This is the first study using 
NMA to compare pulse and continuous systemic therapies for toenail onychomycosis.  
METHODS 
Systematic review 
The systematic review and meta‐analysis was conducted in adherence to the steps outlined in 
the modified PRISMA 2015 Checklist for network meta‐analysis (Table S2). Studies were 
eligible for inclusion if they met the following criteria: studies were randomized controlled 
trials (RCTs) of oral antifungal treatments for toenail dermatophyte onychomycosis in adult 
patients 18 years of age or older and published in the English language. The RCTs could be 
multiple‐arm trials, using placebo or vehicle controls, active comparators (i.e. another 
antifungal treatment) or both. Onychomycosis was required to be diagnosed mycologically by 
study investigators using KOH preparations and fungal cultures. Both tests are used to 
determine whether a fungus is present, the species and viability. Only oral antifungal 
therapies were eligible for inclusion.  
Outcomes of interest included mycological cure, complete cure, adverse events and dropout 
rates due to adverse events caused by the drug. Mycological cure was defined as negative 
results from potassium hydroxide (KOH) microscopy and a negative fungal culture. 
Complete cure was defined as mycological cure in addition to 100% clear nail. Adverse 
events (AEs) was defined as the proportion of patients experiencing any adverse event, and 
dropout rates included patients who stopped participation explicitly due to AEs thought to be 
caused by the drug. The study endpoints chosen were as close to 48 weeks as possible. 
Database search and study selection 
The literature search was conducted using the PubMed database on 27 February 2019 with no 
date limitation. The search query was ‘(onychomycosis OR tinea unguium) AND (oral* OR 
systemic*)’. Reference mining for additional studies or studies missed by the PubMed search 
was also performed. Author NS screened titles and abstracts, reviewed full texts and 
extracted data from eligible studies. Author KAF evaluated the included studies and the 
extracted data. Figure 1 outlines the search and inclusion process.  
Data extraction 
Treatment effects were evalu ted based on intention‐to‐treat (ITT) cure rates wherever 
possible. To ensure consistency among included studies and clinical relevance, some 
decisions regarding treatment and regimens were made about potential studies – for example, 
oral ketoconazole and griseofulvin were excluded because they are no longer indicated for 
onychomycosis due to hepatotoxicity concerns or limited efficacy.16-18 Additionally, 
fluconazole doses of 150, 300 and 450 mg weekly for 9–12 months were collapsed because 
they were shown to have equal efficacy.19 Clinically relevant doses of oral terbinafine (250 or 
500 mg pulsed) and itraconazole (200 or 400 mg pulsed) were included when used for 3–
4 months.  
Quality of evidence and risk‐of‐bias assessment 
The details regarding quality of evidence and risk‐of‐bias assessment for this review can be 
found in Appendix S1 (Supplementary methods).  
Statistical analyses 
Analyses were performed separately for treatment efficacy and adverse events. Prior to our 
multiple‐treatment comparisons, we performed meta‐analyses of randomized controlled trial 
studies for pairwise treatment comparisons using RevMan 5.3 software (The Nordic 
Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Our network meta‐
analyses were performed in RStudio software (version 1.1.463, Rstudio, Inc., Boston, MA, 
USA), whereby the gemtc and ‘pcnetmeta’ packages were used.20, 21 
Network plot of treatments were created for adverse events and efficacy; in such plots, a node 
represents a treatment, while an edge (i.e. the line between two nodes) corresponds to a direct 
comparison between the two treatments, from at least two studies. We performed an arm‐
based network meta‐analysis under a Bayesian random‐effects model that assumed binomial 
likelihood with a probit link function; in the ‘pcnetmeta’ package, Markov chain Monte Carlo 
(MCMC) sampling is done in R through JAGS.20 We used three MCMC chains with 200 000 
iterations per chain, and we used an inverse‐Wishart prior for variance/covariance of random 
effects. We computed relative risks (RRs) and their corresponding 95% credible intervals 
(CIs) to compare treatments with each other for their efficacy and adverse events. Rank 
probabilities were produced and were used to estimate each treatment's surface under the 
cumulative ranking (SUCRA) curve using the equation:  
 
where k = treatment and b = total number of treatments; c = 1 corresponds to the probability 
of the first rank (i.e. the probability of the given treatment being the most effective option).22 
For instance, if a network is constituted of four treatments, each one is given four rank 
probabilities. The first, second, third and fourth rank probabilities correspond to the 
likelihood that the given treatment is the first, second, third and fourth (i.e. least) most 
effective option. The numerator portion of the right‐hand side of the equation (i.e. 
) corresponds to sum of the treatment's cumulative probabilities for the first 
three ranks; by virtue of excluding one rank (i.e. b−1), the cumulative probability for the last 
rank is excluded. The value of the right‐hand side of the equation is always within the range 
of zero to one inclusive.  
For mycological cure, higher occurrence translated to better treatment, while lower 
occurrence corresponded to better treatment for adverse events. 
RESULTS 
Search results 
The PubMed search yielded a total of 1042 items. The total number of items meeting the 
inclusion criteria was 28, which included 13 items selected from reference mining of other 
publications. Detailed information for the studies meeting inclusion criteria is presented in 
Table 1. The quantitative analysis included 22 studies from 20 publications that met the 
criteria required for performing network meta‐analysis (reported cure rates and adverse 
events). At least two RCTs for a specific treatment were required for inclusion into the NMA, 
and each trial must have contributed at least two treatment arms to the network. In total, there 
were 4205 randomized patients included in the NMA.  
The treatments eligible for the network included the following: terbinafine 250 mg daily for 
12 weeks (Terb250_12w), 16 weeks (Terb_16w) and 24 weeks (Terb250_24w); terbinafine 
500 mg daily for 1 week per month, pulsed 3 times (Terb500_p*3); itraconazole 400 mg 
daily for 1 week per month, pulsed 3 times (ITR400*3) or 4 times (ITR400*4); itraconazole 
200 mg daily for 12 weeks (ITR200_12w); and fluconazole 150, 300 or 450 mg once weekly 
for 9–12 months (Flu_9‐12). Ravuconazole, posaconazole and combination therapies could 
not be included in the network. 
We were able to perform NMA for mycological cure and adverse events, but there was a lack 
of studies reporting complete cure for oral antifungals. This is likely because many of the 
studies were conducted prior to the use of consistent outcome measures. 
 
Risk of bias 
The included trials were judged as ‘low risk’, ‘unclear risk’ or ‘high risk’ of bias (Figure S1). 
One study was rated as low risk of bias for all domains while two studies were rated as low 
risk of bias for all but one domain.23-25 Most studies were rated as ‘unclear risk’ for most 
domains as trial procedures were rarely outlined in detail. Appropriate procedures for 
randomization sequence generation (32%) and for allocation concealment (14%) were 
infrequently reported.23-29 Low risk of bias was found for blinding of participants/personnel 
and outcome assessors in 41%23, 24, 26, 29-32 and 18%23, 25, 33, 34 of studies, respectively.  
Quality of evidence 
Evidence for direct comparisons of mycological cure was of moderate or high quality 
(Table S3.1), with the exceptions of Terb250_12w vs. ITR400*3 and Terb250_16w vs. 
ITR400*4 which were of low quality. For adverse event, four of six comparisons were of low 
or very low quality (Table S3.2), with Terb250_12w vs. ITR200_12w and Flu_9‐12 vs. 
placebo the exceptions with moderate quality of evidence.  
Efficacy and safety of oral monotherapy vs. placebo 
Comparing monotherapies to placebo resulted in significantly greater risk ratios (RRs) of 
achieving mycological cure with all treatments. The most successful treatments compared to 
placebo were continuous Terb250_24w with RR = 11.00 (CI 6.08, 19.30) and continuous 
Terb250_16w, RR = 8.90 (CI 4.16, 16.40). The risk of experiencing adverse events in 
patients receiving any treatment was not significantly different from that of placebo (Table 2, 
Figure S2).  
Comparisons of monotherapies 
Continuous regimens of terbinafine were not significantly different in efficacy compared to 
pulse regimens of terbinafine; likewise, continuous and pulse regimens of itraconazole were 
not significantly different. Continuous Terb250_24w was significantly more likely to achieve 
mycological cure than continuous ITR200_12w (RR = 1.63, CI 1.14, 2.26). All other 
continuous and pulse regimens of terbinafine and itraconazole showed similar likelihood in 
achieving mycological cure and were not significantly different from each other (Tables 2 
and 3).  
A continuous treatment of Terb250_24w was significantly more likely to achieve 
mycological cure than weekly Flu_9‐12 (RR = 1.72, CI 1.06, 3.44). Weekly fluconazole was 
not significantly different from any itraconazole regimens, pulse terbinafine and continuous 
12‐ and 16‐week terbinafine (Tables 2 and 3).  
There were not enough studies reporting adverse events for continuous Terb250_24w and 
Terb500_p*3 to be included in the network. However, for all other treatments, the relative 
risk of experiencing adverse events with any other treatment was equivalent (Table 2, 
Figure S3). That is, there was no significant difference in likelihood of experiencing adverse 




Inconsistency analysis performed using the gemtc R package is presented in Table 4. The 
results showed that there was no significant inconsistency between the direct and indirect 
evidence from the network.  
Ranking of treatments by efficacy 
Using SUCRA analysis, continuous Terb250_24w was ranked the most likely to result in 
mycological cure (95.97%), followed by continuous Terb250_16w (70.71%) and continuous 
Terb250_12w (67.42%) (Table 5).  
Ranking of treatments by safety 
Data were coded so that a higher SUCRA probability corresponds to a lower number of 
adverse events. Terbinafine and itraconazole regimens were similar in their probabilities of 
leading to adverse events (Table 6).  
DISCUSSION 
This review and network meta‐analysis was completed in order to compare the effectiveness 
of pulsed and continuous oral antifungal therapies for the treatment of dermatophyte toenail 
onychomycosis. We were able to evaluate mycological cure rates and adverse events for the 
included studies. All oral antifungal regimens were significantly more likely to produce 
mycological cure than placebo. Continuous terbinafine 250 mg for 24 weeks was 
significantly more likely to produce mycological cure than continuous itraconazole 200 mg 
for 12 weeks and weekly fluconazole (150–450 mg). This was reflected in the SUCRA 
rankings, where the treatment with the highest probability of mycological cure was 
continuous terbinafine 250 mg for 24 weeks (95.97%). Quality of evidence for mycological 
cure was mostly moderate or high, providing confidence in the results. 
The FDA‐approved dose of continuous terbinafine 250 mg for 12 weeks was not significantly 
different from other continuous terbinafine regimens (16 and 24 weeks), pulse terbinafine 
500 mg, weekly fluconazole, or itraconazole regimens (continuous itraconazole 200 mg, 3‐ 
and 4‐pulse itraconazole 400 mg) in the ability to produce mycological cure. There were also 
no significant differences between continuous and pulse regimens of itraconazole in 
mycological cure. 
Our meta‐analysis results differ from other findings. A meta‐analysis of terbinafine regimens 
found that continuous treatment was more likely to result in mycological cure than pulsed 
treatments. The same analysis revealed them to have similar efficacy for complete cure.11 In 
contrast, our results suggest that terbinafine treatments are all similar in terms of efficacy. 
Inclusion criteria were similar as well, though a retrospective study was used in the other 
meta‐analysis.  
In terms of safety, the terbinafine pulse and continuous regimens were not significantly 
different; similarly, the itraconazole pulse and continuous therapies were not significantly 
different. In addition, terbinafine, itraconazole and fluconazole did not significantly differ in 
their safety and did not significantly differ from placebo. We did not have sufficient data to 
include continuous terbinafine for 24 weeks (Terb250_24w) or pulse terbinafine 
(Terb500_p*3) in the adverse events analysis. Quality of evidence for adverse events was low 
or very low for most comparisons, and thus, we cannot have confidence in the SUCRA 
rankings. 
Surface under the cumulative ranking rankings are able to summarize the efficacy of 
treatments, but may be misleading outside of the context of the relative effects of the NMA.35
A treatment's surface under the cumulative ranking curve (SUCRA) can be described as a 
numerical rank, where the rank could be in relation to adverse events associated with the 
treatment or the treatment's efficacy. Easily misinterpreted, the literature cautions against 
taking SUCRA rankings at surface value – specially when making clinical decisions.35, 36 
SUCRA rankings are arguably meaningless on their own for several reasons; namely, the 
estimation of SUCRA does not take into account the certainty level of the evidence, and thus 
may be computed from evidence with low certainty. Evidence with high imprecision (i.e. a 
high degree of uncertainty) arguably leads to high imprecision of a treatment's rank, which in 
turn explains how the difference in rank between two treatments could be due to chance; in 
other words, the highest‐ranked and lowest‐ranked treatments may not be significantly 
different from each other in terms of efficacy or occurrence of adverse events (thus, their 
difference in rank is due to chance alone). Therefore, our SUCRA values – as per adverse 
events – of approximately 92% and 33% for ITR400*4 and placebo, respectively, and the 
statistically non‐significant difference between the two, in terms of occurrence in adverse 
events (risk ratio = 0.475, 95% CI = 0.122, 1.060), is not incongruent.  
Based on the model proposed by Baker et al. and considering the fungal life cycle, pulse 
therapy should theoretically be as effective as, or more effective than, continuous therapies.37 
With pulse therapy, the sudden high concentration of an antifungal drug eliminates hyphae, 
preventing the formation of new spores but perhaps sparing already‐present spores. During 
the ‘off’ portion of pulse therapy, these spores may sense a more favourable host 
environment and germinate into hyphae if the drug concentration falls low enough. Thus, 
hyphae would be present that the next pulse could eliminate. With continuous therapies, a 
high concentration of drug in the nail is maintained for a long period of time, eradicating 
hyphae and preventing the germination of existing spores (and possibly eliminating them as 
well). There is no ‘off’ period for the spores to become more susceptible hyphae, so it can be 
assumed that high, stable drug concentrations in the nail must be maintained for spores to be 
eliminated. In practice, neither continuous nor pulse therapy is necessarily better – in both 
cases, patients should be clipping their nails, which manually decreases the fungal load from 
the nail. We can speculate that in the case of antifungal pulse therapy, it is possible that the 
drug concentration in the nail is maintained during the ‘off’ period at a level that is not 
favourable to induce hypha formation. In both continuous and repeated pulse therapies, it 
may be that residual spores that have not been eliminated by the end of therapy are left to 
germinate, possibly contributing to the recalcitrant nature of onychomycosis.  
The results generated by our NMA suggest that continuous terbinafine (24 weeks’ duration) 
treatment is most likely to result in mycological cure, a treatment that is twice the length of 
approved treatment. Studies support terbinafine courses lasting <24 weeks being equally 
effective in the treatment of onychomycosis, and the drugs are detectable in nail clippings as 
soon as 3 weeks into treatment.38-40 Thus, our results complement these findings as we found 
no significant differences between continuous terbinafine regimens. Additionally, terbinafine 
has been cited as a superior drug in terms of its fungicidal action, which may be explained by 
its ability to suppress conidium production in T. rubrum.41, 42 In theory, pulse therapy presents 
itself as a more advantageous strategy for reasons discussed. Ultimately, the published 
evidence demonstrates that there are no differences in efficacy or safety between pulse and 
continuous regimens of terbinafine and no differences between pulse and continuous 
regimens of itraconazole. More research about pulse therapy efficacy and safety is required 
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Figure 1  







Table 1. List of included studies 
 




Dropout rate (due to 
AE/drug) MC CC 
Included in NMA  
Billstein et al. 
(1999)  
n = 63 
mean age = 42.3–46.9 
T1. TERB 250 mg 
T2. TERB 250 mg 
T3. TERB 250 mg 
P. placebo 
T1. daily for 12 weeks 
T2. daily for 16 weeks 
T3. daily for 24 weeks 
P. daily for 24 weeks 
T1. 11/15 (73%) 
T2. 10/14 (71%) 
T3. 17/18 (94%) 
P. 0/16 
– 48 – – 
Bräutigam et al. 
(1996)  
n = 170 
mean age = 49 
T1. TERB 250 mg 
T2. ITR 200 mg 
Daily for 12 weeks 
T1. 70/86 (81%) 
T2. 53/84 (63%) 
– 52 
T1. 38/95 (40%) 
T2. 47/98 (48%) 
T1: 3/95 (3.15%) 
T2: 4/98 (4.1%) 
De Backer et al. 
(1996)  
n = 372  
T1. TERB 250 mg 
T2. ITR 200 mg 










T1. 71/186 (38.6%) 
T2. 65/186 (35.4%) 
– 
Degreef et al. 
(1999)  
n = 292 
ages 18–65 
T1. ITR 200 mg 
T2. TERB 250 mg 






T1. 32/146 (22%) 
T2. 34/146 (23%) 
T1. 2/146 (1.4%) 
T2. 11/146 (7.5%) 
Drake et al. 
(1997)  
n = 358 
ages 18–70 
T1. TERB 250 mg 
T2. TERB 250 mg 
P. placebo 
T1. daily for 12 weeks + placebo 
12 weeks 
T2. daily for 24 weeks 





P. 6/71 (9%) 
– 48 9/358 (2.5%) 
T1. 2/142 (1.4%) 
T2. 3/145 (2.1%) 




Dropout rate (due to 
AE/drug) MC CC 
Elewski et al. 
(2012)  
n = 218  
T1. POS 100 mg 
T2. POS 200 mg 
T3. POS 400 mg 
T4. POS 400 mg 
T5. TERB 250 mg 
P. placebo 
T1. daily for 24 weeks 
T2. daily for 24 weeks 
T3. daily for 24 weeks 
T4. daily for 12 weeks 
T5. daily for 12 weeks 
























T1. 30/37 (83%) 
T2. 29/37 (78%) 
T3. 26/36 (72%) 
T4. 27/36 (75%) 
T5. 24/36 (67%) 
P. 25/36 (71%) 
T1. 1/37 (2.7%) 
T2. 2/37 (5.4%) 
T3. 4/36 (11%) 
T4. 4/36 (11%) 
T5. 0/36 
P. 1/36 (2.7%) 
Elewski et al. 
(1997)  
n = 68 
ages 18–70 
T1. ITR 200 mg 
P. placebo 
Daily for 12 weeks 
T1. 24/35 (69%) 
P. 2/33 (6%) 
– 48 
T1: 19/36 (53%) 
P: 21/37 (57%) 
– 
n = 82 
ages 23–69 
T1. ITR 200 mg 
P. placebo 
T1. 18/38 (47%) 
P. 3/35 (9%) 
T1: 24/39 (62%) 
P: 16/35 (46%) 
n = 73 
ages 22–69 
T1. ITR 200 mg 
P. placebo 
T1. 17/37 (46%) 
P. 1/36 (3%) 
T1: 28/37 (76%) 
P: 23/37 (62%) 
Goodfield 
(1992) 
n = 75  
T1. TERB 250 mg 
P. placebo 
Daily for 12 weeks 
T1. 37/45 (82%) 
P. 3/25 (12%) 
– 36 
T1. 25/45 (33%) 
P. 14/25 (41%) 
– 
Gupta et al. 
(2006)  
n = 70  
T1. ITR 400 mg 
T2. TERB 250 mg 
T1. daily for 1 week/month × 3 





– 48 – T1. 1/35 (2.9%) 




Dropout rate (due to 
AE/drug) MC CC 
Gupta et al. 
(2001) B  
n = 101 
age ≥60 
T1. TERB 250 mg 
T2. ITR 400 mg 
T1. daily for 12 weeks 
T2. daily for 1 week/month × 3 




T1. 5/50 (10%) 
T2. 7/51 (13.7%) 
0/101 
Gupta et al. 
(2009)  
n = 142  
T1. TERB 250 mg 
T2. TERB 250 mg 
T3. ITR 400 mg 
T1. 4 weeks on, 4 off, 4 on 
T2. daily for 12 weeks 
T3. daily for 1 week/month × 3 
T1. 33/63 
(52.4%) 




T1. 14/63 (22.2%) 
T2. 7/40 (17.5%) 
T3. 4/39 (10.3%) 
T3. 2/39 (5.1%) 
Havu et al. 
(1997)  
n = 129 
median age = 41–45 
T1. ITR 200 mg 
T2. ITR 400 mg 
T1. daily for 12 weeks 






T1. 11/65 (17%) 
T2. 9/64 (14%) 
T1. 3/65 (4.6%) 
T2. 3/64 (4.7%) 
Ling et al. 
(1998)  
n = 384  
T1. FLU 450 mg 
T2. FLU 450 mg 
T3. FLU 450 mg 
P. placebo 
T1. weekly for 4 month + placebo 
for 5 month 
T2. weekly for 6 month + placebo 
for 3 month 
T3. weekly for 9 month 
P. weekly for 9 month  
T1. 28/96 (29%) 
T2. 32/94 (34%) 
T3. 50/98 (51%) 
T4. 6/96 (6.25%) 
– 36 
T1. 74/96 (77.1%) 
T2. 76/94 (80.8%) 
T3. 71/98 (72.4%) 
P. 70/96 (73%) 
T1. 6/96 (6.25%) 
T2. 1/94 (1%) 
T3. 3/98 (3.1%) 
P. 7/96 (8.3%) 
Scher et al. 
(1998)  
n = 439 
ages 18–70 
T1. FLU 150 mg 
T2. FLU 300 mg 
T3. FLU 450 mg 
P. placebo 
FLU. once weekly for 12 months 
P. once weekly for 12 months 
T1. 37/89 
(41.6%) 
T2. 44/88 (50%) 
T3. 49/92 
(53.2%) 
P. 11/92 (12%) 
– 52 
T1. 74/89 (83%) 
T2. 74/88 (84%) 
T3. 79/92 (86%) 
P. 72/92 (78%) 
T1. 4/89 (4.5%) 
T2. 9/88 (10.2%) 
T3. 5/92 (5.4%) 
P. 6/92 (6.5%) 




Dropout rate (due to 
AE/drug) MC CC 
Sigurgeirss‐on 
et al. (1999)  
n = 496 
ages 18–75 
T1. TERB 250 mg 
T2. TERB 250 mg 
T3. ITR 400 mg 
T4. ITR 400 mg 
T1. daily for 12 weeks 
T2. daily for 16 weeks 
T3. daily for 1 week/month × 3 


















T1. 55/126 (44%) 
T2. 61/126 (48%) 
T3. 60/124 (48%) 
T4. 60/120 (50%) 
– 
Tosti et al. 
(1996)  
n = 60 
mean age = 47.3 
T1. TERB 250 mg 
T2. TERB 500 mg 
T3. ITR 400 mg 
T1. daily for 16 weeks 
T2. daily for 1 week/month × 4 





T3. 15/20 (75%) 
– 40 
T1. 1/19 (5.3%) 
T2. 1/21 (4.8%) 
– 
van der Schroeff 
et al. (1992)  
n = 120  TERB 250 mg 
T1. daily for 6 weeks + 18 weeks 
placebo 
T2. daily for 12 weeks + 12 weeks 
placebo 





T3. 28/40 (70%) 
– 48 
T. 37/117 (32%) 
P. 11/80 (14%) 
TERB: 3/117 (2.6%) 
Warshaw et al. 
(2005)  
n = 306  
T1. TERB 250 mg 
T2. TERB 500 mg 
T1. daily × 12 weeks 










T1. 9/153 (5.9%) 
T2. 8/153 (5.2%) 
Watson et al. 
(1995)  
n = 111  
T1. TERB 250 mg 
P. placebo 
Daily for 12 weeks 
T1. 33/56 (59%) 
P. 5/55 (9%) 
– 48 
T1. 46/56 (82.1%) 
P. 40/55 (72.7%) 
T1. 1/56 (1.8%) 
P. 2/55 (3.6%) 




Dropout rate (due to 
AE/drug) MC CC 
Yadav et al. 
(2015)  
n = 76 
mean 
age = 42.51 ± 13.6 
T1: TERB 250 mg 
T2: TERB 500 mg 
T1. daily for 12 weeks 










24 – – 
Not included in NMA  
Gupta et al. 
(2005) B  
n = 130  
T1. RAV 200 mg 
T2. RAV 100 mg 
T3. RAV 400 mg 
P. placebo 
T1. daily for 12 weeks 
T2. weekly for 12 weeks 
T3. weekly for 12 weeks 
P. daily for 12 weeks 
T1. 20/34 (59%) 
T2. 5/39 (13%) 
T3. 3/36 (8%) 
P. 3/20 (15%) 
– 48 – – 
Gupta et al. 
(2001)  
n = 176 
mean age 53.1–54.5 
T1. ITR 400 mg + 
TERB 500 mg 
T2. TERB 500 mg 
T1. ITR daily for 
1 week/month × 2, followed by 
TERB daily for 1 week 










T1. 12/81 (14.8%) 
T2. 22/95 (23.1%) 
T1. 2/81 (2.5%) 
T2. 2/95 (2.1%) 
Gupta et al. 
(2005)  
n = 73  
T1. CPX + TERB 
250 mg 
T2. CPX + TERB 
250 mg 
T3. TERB 250 mg 
T1. daily for 48 weeks + daily 
4 weeks on, 4 off, 4 on 
T2. daily for 48 weeks + daily for 
12 weeks 





T3. 12/23 (56%) 
– 48 
T1. 4/20 (20.5%) 
T2. 5/24 (21.4%) 
T3. 5/23 (22%) 
0/73 
Jennings et al. 
(2006)  
n = 504 
mean age = 49.1 
T1. TERB 250 mg 
T2. TERB 250 mg + 
debridement 









48 171/504 (33.9%) 
T1. 9/243 (3.7%) 
T2. 5/246 (2.03%) 
Sigurgeirss‐on 
et al. (2006)  
n = 2005 
mean age 50.8 
T1. TERB 250 
T2. TERB 350 
T1. daily for 12 weeks 
T2. daily for 2 weeks, 2 weeks 










T1. 109/994 (11%) 
T2. 111/1011 (11%) 
T1. 16/994 (1.6%) 
T2. 28/1011 (2.8%) 




Dropout rate (due to 
AE/drug) MC CC 
Sigurgeirss‐on 
et al. (2013)  
n = 584  
T1. ALBA 100 mg 
T2. ALBA 200 mg 
T3. ALBA 400 mg 
T4. ALBA 400 mg 
P. placebo 
T1. 1x weekly, 36 weeks 
T2. 1x weekly, 36 weeks 
T3. 1x weekly, 36 weeks 
T4. 1x weekly, 24 weeks + 
placebo 12 weeks 



















52 414/584 (71%) 
T1. 11/117 (9.4%) 
T2. 6/117 (5.1%) 
T3. 7/116 (6.0%) 
T4. 16/117 (13.7%) 
P. 8/115 (6.9%) 
Succi et al. 
(2013)  
n = 41,  
mean age 50–56 
T1: TERB 250 mg 
T2: TERB 500 mg 
T1: daily for 1 week/month + nail 
abrasion, for 6 month 
T2: daily for 1 week every 
2 months + nail abrasion, for 
6 month 
T1. 4/18 (22.2%) 





48 T1. 1/18 (5.5%) – 
Watanabe et al. 
(2018)  
n = 153 
mean age = 58.4 
T1: F‐RVCZ 100 mg 
P. placebo 
daily for 12 weeks 
T1. 82/101 
(82%) 






T1. 84/101 (83.2%) 
P. 42/52 (80.8%) 
– 





Table 2.  
Relative risks and corresponding 95% credible intervals. Each cell gives the effect of the column‐defining intervention relative to the row‐defining intervention. 
RRs above the labels are mycological cure, and RRs below the labels are adverse events. Dashes indicate that AE data were not available for continuous terbinafine 






















































































































– – – – – – – Terb250_24w  1.340 (0.904, 
2.380) 
– – – – – – – – Terb500_p*3  
• The bold texts in the table correspond to the following abbreviations: Terbinafine 250 mg daily for 12 weeks (Terb250_12w), 16 weeks (Terb_16w), and 24 weeks 
(Terb250_24w); Terbinafine 500 mg daily for one week per month, pulsed 3 times (Terb500_p*3); Itraconazole 400 mg daily for one week per month, pulsed 3 
times (ITR400*3) or 4 times (ITR400*4); Itraconazole 200 mg daily for 12 weeks (ITR200_12w); and Fluconazole 150 mg, 300 mg, or 450 mg once weekly for 9 to 
12 months (Flu_9‐12).  
 
Table 3.  
Summary of NMA comparisons of the included systemic treatments for mycological cure (efficacy).  
Treatments in the same column are not significantly different from each other.  
Treatments in different columns are significantly different from each other 
 
Treatment Treatment Control 
Terb250_24w Flu_9‐12 Placebo 
Terb250_16w ITR200_12w  
Terb250_12w Terb250_16w  
ITR400*3 Terb250_12w  
ITR400*4 ITR400*3  
Terb500*3 ITR400*4  




Table 4.  
 




Treatment 1 Treatment 2 P‐value for inconsistency  
ITR200_12w Placebo 0.8536 
ITR200_12w Terb250_12w 0.8547 





Treatment 1 Treatment 2 P‐value for inconsistency  
ITR200_12w Placebo 0.7612 
ITR200_12w Terb250_12w 0.7522 
Placebo Terb250_12w 0.7906 
 
  
Table 5.  
 

















Table 6.  
 
Surface under the cumulative ranking (SUCRA) curve for adverse events.  
A higher probability corresponds to a lower number of adverse events  
 
 
















The treatments eligible for the network included the following: terbinafine 250 mg daily for 12 weeks 
(Terb250_12w), 16 weeks (Terb_16w) and 24 weeks (Terb250_24w); terbinafine 500 mg daily for 1 week per 
month, pulsed 3 times (Terb500_p*3); itraconazole 400 mg daily for 1 week per month, pulsed 3 times 
(ITR400*3) or 4 times (ITR400*4); itraconazole 200 mg daily for 12 weeks (ITR200_12w); and fluconazole 
150, 300 or 450 mg once weekly for 9–12 months (Flu_9‐12). Ravuconazole, posaconazole and combination 
therapies could not be included in the network. 
We were able to perform NMA for mycological cure and adverse events, but there was a lack of studies 
reporting complete cure for oral antifungals. This is likely because many of the studi s were conducted prior to 
the use of consistent outcome measures. 
 
